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EPA Priorities for Biologic Markers Research
in Environmental Health
by John R. Fowle, liii and Ken Sexton1
Recent advances in molecular and cellular biology allow for measurement ofbiologic events or substances
that may provide markers of exposure, effect, or susceptibility in humans. The application ofthese new and
emergingtechniquestoenvironmental health offersthepossibilityofsignificantlyreducingtheuncertainties
thattraditionallyhamperriskassessments.TheU.S.Environmental ProtectionAgency(EPA) healthresearch
program emphasizes the validation of appropriate biologic markers and their application to high-priority
Agency issues. The rationale for EPA's biomarker research program is presented, and future research
directions are discussed. Exposure biomarkers will receive most ofthe research emphasis in the near term,
particularly body burden indicators ofexposure to high-priority chemicals, such as benzene, ozone, selected
heavy metals, and organophosphate pesticides. Research on effects biomarkers will attempt to validate the
relationshipbetweentheobservedbiological effectsandadverse healthconsequencesinhumans,especiallyfor
cancer, pulmonary toxicity, immunotoxicity, and reproductive/developmental toxicity.
Introduction
The United States Environmental Protection Agency
(EPA) is responsible for safeguarding public health from
the adverse consequences of environmental exposures.
This mandate requires that EPA be both a regulatory
agency and a science agency. As aregulatory agency, EPA
enforces more than a dozen major environmental laws,
such as the Clean Air Act and the Toxic Substances
ControlAct. As a science agency, EPAcarries outrelevant
and timely research to ensure that regulatory and policy
decisions are based on sound scientific information (1).
The primary goal of EPAs health research program is
to reduce or eliminate critical uncertainties associated
withhealthriskassessments forenvironmental exposures.
To accomplish this, the EPA health research program
focuses on developing an understanding of the relation-
ships among pollutant sources, environmental exposures,
and related human health effects. It spansthe gamutfrom
long-range basic research to short-term applied research
andfunctionsprimarilyattheinterfacebetweenthesetwo
ends of the spectrum. The central position occupied by
EPA's research program requires EPA scientists to be
cognizant ofimportant breakthroughs in the basic biolog-
ical sciences (e.g., molecular biology, genetics, immunol-
ogy) and capable of applying these scientific advances to
real-world problems facing the Agency. Conversely, EPA
scientists must be knowledgeable about contemporary
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regulatory issues and conceptualize the basic research
questions that need to be addressed (1,2).
Biologic markers provide a good example of how pro-
gress in basic research can significantly advance the
state-of-the-science in an applied research area such as
health risk management. The EPArelies heavily on quan-
titative assessment of environmental health risks as the
scientificbasisfordecisions abouthowbesttoguardpublic
health. By providing the methods to make biologic mea-
surements of variations in genes, cells, and physiologic
processes, the revolution in molecular biology has paved
the way to measure environmental exposures more accu-
rately and precisely, to define better associated health
effects, and to improve the determination ofsusceptibility
to pollutant exposures (3). These scientific advances will
lead to better characterization of actual human health
risks and a more solid scientific footing for policy and
regulatory decisions.
The EPAhealthresearchprogramis designedtorecog-
nize the significance of these new methods, to identify
those that are most relevant to the problems confronting
the Agency, to encourage the development and promote
the validation ofsuitable biologic markers, to advance the
application of these techniques to environmental risk
assessment, and to aid EPA decision makers in under-
standing and using biomarker data. The current and
future importance of biologic markers for improving
health risk assessments is well recognized within the
Agency and has prompted state-of-the-art evaluations for
the role ofbiologic markers in epidemiology (4), reproduc-
tive toxicology (5), pulmonary toxicology (6), and human
exposure assessment (7).FOWLE AND SEXTON
Context for Biomarkers Research
Cascade ofEvents from Exposure to Effect
Understanding the human health risk associated with
environmental exposures involves defining the cascade of
events between exposure to an environmental agent and
the resulting health effect. To cause a health effect, a
pollutant must be absorbed into the body, reach a target
organ, andresultin abiological change. Formostenviron-
mental pollutants, little is known about this flow ofevents
between exposure and health effect. Biomarkers have the
potential to shedlight on thefactorsinfluencinghowmuch
of a pollutant is absorbed, how much reaches a target
organ, and howtarget dose is related to effect. Definitions
of terms that are important in biomarker research are
given in Table 1.
The EPAhas adoptedthefollowinggeneraldefinition of
a biologic marker or "biomarker": a measurement of
environmental pollutants or their biological consequences
after the contaminants have crossed one of the body's
boundaries andenteredhumantissues orfluids, andwhich
serves as an indicator of exposure, effect, and/or suscep-
tibility.
The cascade ofeventsbetween exposure andenvironmen-
tallyinduced diseaseis shownschematicallyinFigure 1. The
boxes represent events that may potentially be defined,
either qualitatively or quantitatively, by biomarkers.
Table 1. Key definitions for EPA's biomarker research program.
Term Definition
Concentration Amount ofmaterial (chemical substance) per unit
ofvolume or mass in an environmental sample
Exposurea Contact between an environmental pollutant and
a living organism(s) (e.g., human, indicator
organism, ecosystem); this may result from a
single challenge or from contact at a given
concentration over time
Absorbed dosea Amount ofmaterial that crosses one or more of
(internal dose) the body's boundaries; often absorbed dose is
best measured by the area under the curve of
intake versus time
Delivered dosea Amount ofthe absorbed dose and/or its
(target or metabolites that reaches the target (e.g., tissue,
biologically cell); often, delivered dose is best measured by
effective dose) the area under the curve oftissue concentration
versus time
Body burden Amount and distribution ofmaterial and/or its
metabolites in the body
Biological effect A measurable response in a molecule, cell, tissue,
or fluid
Health effect Abiological effect that causes dysfunction, injury,
illness, or death
Susceptibility Increased or decreased resistance to absorption
ofand/or effect from chemical substances due to
genetic predisposition, environmental character-
istics, lifestyle factors, age, gender, or ethnicity
1ime component may be critical.
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FIGURE 1.Asimplifieddiagramofthecascadeofeventsfromexposureto
healtheffects showingtherelationships amongexposuremarkers,effects
markers, and susceptibility markers.
Exposure markers are indicators ofabsorbed or target
dose (including an absorbedpollutant, itsmetabolite(s), or
products resulting from interaction with endogenous sub-
stances), which are measured in a body tissue, fluid, or
exereta. These biomarkers provide information concern-
ing the chemicals to which humans are exposed. Most
exposure biomarkers are indicators ofabsorbed dose.
Effect markers are indicators of biological response.
These biomarkers provide information concerning the
likely health outcomes associated with different target
doses of environmental pollutants or their metabolite(s).
Susceptibility markers are indicators of whether an
individual is more or less biologically susceptible to
environmental health effects. Sensitivesubpopulations, for
example, can be pinpointed by biomarkers that measure
increased absorption rate or a more severe biologic
response to a given environmentaLexposure.
Fisk Assessment Basis for Biomarkers
Research
Estimating theriskassociatedwith exposure to agiven
pollutantinve esevaluatingthelikelihood andmagnitude
of resulting health outcomes. The EPA has adopted a
formalrisk assessmentprocess, the steps ofwhichmirror
the flow ofevents from exposure to effect (8). These steps
also identify critical questions in environmental health
research: a) hazard identification-is the agentcapable of
causing an adverse effectin humans? b) Exposure assess-
ment-what exposures occur or are anticipated to occur
for human populations? c) Dose-response assessment-
what is the quantitative relationship between dose and
effectinhumans? andd) Riskcharacterization (based on a
synthesis ofdose-response and exposure assessments)-
what is the estimated human health risk from the antici-
pated environmental exposures?
Historically, exposure assessments have relied almost
exclusivelyonmeasurements ormodelpredictions ofpollu-
tant concentrations in relevant environmental media (i.e.,
air,water,food, soil), whereas dose-response assessments
have been based primarily on animal toxicology data. In
recentyears, however, attention hasfocused ontheimpor-
tance of obtaining information about actual exposures
experienced by humans and on the necessity of under-
standing the relationship between exposure and dose
(pharmacokinetics) and between dose and effect (phar-
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macodynamics) in human populations. It is now clear that
significant improvements in health risk assessments can
onlybe achieved bytargetingresearch ontheseimportant
issues (9).
The advent ofbiologic markers promises to revolution-
ize both exposure and effects assessments (5,6,10). As
shown in Figure 1, biomarkers can provide exposure,
effects, and susceptibility information based on a knowl-
edge of the key events (e.g., absorbed dose, target dose,
biological effect) thatintervene between human exposures
and related disease or injury. Application of exposure
biomarkers to human populations will allow individuals to
be classified more precisely according to exposures (e.g.,
high versus low exposures). Similarly, effect biomarkers
will provide epidemiologists with the ability to better link
human exposures with environmentally induced disease.
Susceptibilitymarkerswill makeitpossible to moreeasily
identify susceptible individuals and groups so that they
can be considered adequately in the assessment and man-
agement of risk. Overall, biologic markers offer the pos-
sibility of using human data to make health risk assess-
ments more meaningful, realistic, and cost effective.
EPA's Role in Biologic Markers Research
The EPA commitment to promoting the development
and use of biologic markers stems from an awareness of
their potential to significantly improve the accuracy of
health risk assessments. From the EPA perspective, bio-
logic marker research includes four major questions (10).
a) Development-which actions must be taken to develop
new methods and techniques for measuring biologic
markers? b) Validation-what scientific evidence is neces-
sary to show conclusively that a biologic marker is an
indicator of exposure, effect, or susceptibility? c) Appli-
cation-how, when, where, andwhy should biologic markers
be used to obtain relevant information in human popula-
tions? and d) Interpretation-what are the implications of
biologic marker data for risk assessment, risk manage-
ment, and risk communication decisions?
Together, the answers to these questions form a path-
way leading to more informed decisions about the protec-
tionofpublichealth. Therespectiveroles ofEPAscientists
in addressing these questions are summarized in Table 2.
Future Research Directions
EPA scientists develop methods and make measure-
ments aimed at constructing three types of predictive
models: integrated human exposure models, phys-
iologicallybasedpharmacokinetic models, and biologically
based dose-response models (9). Development, validation,
and application of biologic markers are often an integral
part of this research. The following discussion summa-
rizes future research directions for EPA's biomarkers
program.
Exposure Biomarkers
One ofthemajor areas ofconcerninbiomarker develop-
ment is the specifi'city ofthe measurement. Current reg-
ulations to protect public health tend to be chemical
specific. Therefore, biomarkers are needed to identify and
characterize exposures to specific environmental pollu-
lable 2. The role ofEPA scientists in the development, validation, application, and interpretation ofbiologic markers (10).
Activity Definition Role of EPA scientists
Development Generate new methods and techniques to measure Most development activites are conducted by organizations
biochemical, molecular, genetic, immunologic, or physiologic like NIH that perform basic biological research. Although
indicators ofexposure, effects, and susceptibility development ofbiologic markers is a natural outgrowth of
some EPA research, EPA scientists are primarily
responsible for recognizing the potential environmental
health applications ofemerging technologies
Validation Assemble adequate scientific evidence to show that the A major focus ofthe EPA research program is establishing
biologic marker measures what it purports to measure the validity ofexisting biologic markers by documenting
their accuracy, precision, reproducibility, reliability, etc., in
human populations
Application Use biologic markers to measure exposure, effects, or The EPA research program actively promotes the
susceptibility in human populations application ofvalidated biologic markers to human
populations in order to improve decisions about the
protection ofpublic health
Interpretation Risk assessment: apply biologic marker information to EPA scientists develop risk assessment guidelines, do
qualitative and quantitive evaluation ofhealth risks from qualitative and quantitative health risk assessments, and
environmental exposures identify associated research needs
Risk management: select, implement, and enforce cost- EPA scientists put risk assessments into perspective for
effective risk prevention and risk reduction strategies based decision makers, provide information on comparison of
on consideration ofrisk assessment information, as well as risks from various sources, and evaluate residual risks that
evaluation ofsocial, economic, and engineering issues remain after controls are implemented
Risk communication: characterize and explain EPA scientists participate in specifying and communicating
environmental health risks and actions to prevent or reduce the basis for risk assessment and risk management
unacceptable risks decisions and in explaining their impact on public health
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tants. To meet Agency needs, biomarker research will
emphasize twotypes ofmarkers: those that are compound
specific (e.g., benzene, trichloroethylene, acrylamide,
styrene, nicotine, lead) and those that are indicators of
relevant classes of compounds (e.g., dioxins, PCBs). The
program will include three related methods development
activities (7): a) evaluation of scientific information with
regardtonewlydevelopedbiomarkers andrelatedtechnol-
ogy, including detection methodology (i.e., can they be
adapted forAgency use?); b) laboratory studies to ensure
full characterization of potentially useful biomarkers,
refinement/development of pharmacokinetic models for
the analysis of biomarker data, and development of
monitoring methods and devices for detecting and quan-
tifying biomarkers, and c) field trials ofbiologic markers,
methods, devices, models, and protocols.
The mostpromisingbiomarkers ofexposure in the near
term arebodyburden measurements ofspecific chemicals
found in the blood, urine, saliva, and breath. These
methods yield data directly usable in risk assessment
models. Nonspecific markers of exposure, such as conju-
gate complexes or elevated/depressed enzyme levels, pro-
videindirectevidenceaboutexposuretoaspecificchemical
or chemical mixture.
Inthelongerterm, characterization ofDNAandprotein
adducts (including hemoglobin, albumin, and membrane
receptor proteins) to detect exposure to toxic chemicals
will be emphasized. Although these measures and others,
such as sister chromatid exchange (SCE), may be used as
first-tier tests to suggest that exposure to a chemical has
occurred,follow-up chemical-specific tests mustbeapplied
to provide data that are directly useful for exposure
assessment and risk characterization.
The term "reconstructive exposure assessment" refers
to. the use of dose information to estimate past human
exposures in a quantitative fashion. For reconstructive
exposure assessment to be a practical quantitative tool, a
model based on the pharmacokinetics of the particular
chemical is necessary. Physiologically based pharma-
cokinetic models, together with measurements ofthe spe-
cific biomarker, form the basis to link exposure, dose, and
effect. The following areas have been identified as the
highest priorityforfuture research: a) validate and apply
biomarkers of body burden (e.g., blood and urine sam-
pling) forfield and epidemiological studies inhuman popu-
lations, develop pharmacokinetic models for estimating
dose from tissue levels and for estimating/reconstructing
external exposures from dose measures, and identify
appropriate metabolites as body burden measures and b)
refine and validate new body burden markers (e.g.,
receptor-xenobiotic complexes, protein adducts, and DNA
adducts) for high-priority chemicals.
Effects Biomarkers
The EPA compares the benefits ofreduced risk versus
the costs ofcontrols in the vast majority ofits regulatory
decisions. Thephysiological responses that serve as effect
biomarkers are, however, now disease end points. There-
fore, the relationship between the biomarker and the
disease must be known if biomarkers are to be directly
relevant for regulatory decisions. The primary goal of
EPA's effect biomarkers research will be to improve the
interpretation of markers as an early indicator of an
adverse health effect, with primary emphasis on cancer,
pulmonary toxicity, neurotoxicity, and reproductive/
developmental toxicity. Secondary emphasis will be put on
immunotoxicity, heritable genetic mutations, and hepato-
toxicity. For each of the critical health end points, key
research needs are outlined below.
Cancer. Recent advances in cancer biology are fueling
the development ofmore realistic cancer risk assessment
models. Two of these advances are the identification of
tumor growth genes (oncogenes) and tumor anti-growth
genes(suppressorgenes). Studies onthesegenesinmalig-
nant cells of certain tumor types, such as colon cancer,
showthatthegenomeofthesecellscontainsmorethanone
genetic change, and suggest that many mutations (per-
haps 10-15) must occur before cancer results (11). Im-
proved knowledge ofthe mechanism ofcancer production
following chemical exposure will allow the development of
measures for evaluating whether humans have been
exposed to carcinogens. Thevalidation ofthese mechanis-
tic studies will be an important component of EPA's bio-
markers program.
Scientists currently evaluate exposure to carcinogens
with DNA and protein adducts because oftheir chemical
or chemical-class specificity. Many uncertainties exist,
however, concerning the relationship of these substances
to cancer, and many technical difficulties need to be
resolved to expand promising detection techniques (e.g.,
the32P-postlabelingtechnique) to awidevarietyofchemi-
cal classes.
Initialeffortswillfocus onthevalidation and application
ofDNAadducts, stressinglesion formation, rate ofrepair,
andtissuedistribution. Theprimaryresearchgoalswillbe
to define the dose-response relationship between the
adduct and health effect, to define the relationship
between measured adduct levels and target tissue levels
(when appropriate), to determine the lifetime of the
adduct, to establish adduct reference standards, and to
extend the methodology to a wide variety of chemical
classes.
Protein adducts will also receive attention, with
emphasis placed on threeprimarygoals: to relate adducts
to target site dose-response, to develop and improve
methodologies and techniques (e.g., preparation and iden-
tification of adducts), and to evaluate, refine, and validate
biomarkers for application to human populations (12,13).
Amajoraimforboth DNAandproteinadductsresearch
will be to develop adducts for evaluating exposure to
pollutant mixtures (includingreference adductstandards)
and to identify patterns or arrays ofadducts characteris-
tic ofchemical classes. In addition, current techniques in
molecular carcinogenesis will be applied to develop bio-
markers for environmental carcinogenesis, including
alterations in DNA, alterations in the expression or struc-
ture of proteins or enzymes, ultrastructural changes,
growth factors, and receptors/receptor-xenobiotic com-
plexes.
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Pulmonary Toxicity. The lung is the primary route of
entry for air pollutants. Most of the regulations promul-
gated under the Clean Air Act are based on data showing
effects to the cardiopulmonary system. Because of the
lung's relative accessibility, the EPAand others have used
biomarkers from lung fluids and tissue to assess human
exposure to airpollutants. Mostofthese studies havebeen
conducted in a clinical setting, often with invasive tech-
niques. A major goal of research on pulmonary effects
biomarkers is to develop, validate, and apply less invasive
markers onlargerpopulations thanis nowpossible(6).The
focus ofthisworkis on nasal lavage (NAL), andthe goalis
toimprovethetechniquefor useinclinical andfieldstudies
to obtain information about human exposures to air pollu-
tants and resulting biologic effects. NAL values are com-
pared to results from bronchoalveolar lavage (BAL) and
parallel studies are conducted in experimental rodents to
determine the linkage between biomarker measures and
adverse effects.
Current efforts involve characterization of the normal
parameters forthe cellular and biochemical components of
NAL. The purpose is to develop baseline values and to
identifybiomarkercandidatesforfurthercharacterization
and validation for use in human studies. Biomarkers cur-
rently under study include: macrophage proteins, lipid
peroxidation products, DNA and protein adducts, and
indicators ofinflammation.
Future efforts will be designed to identify indicators of
pulmonary damage in the urine of exposed individuals
usingtechniquesthat arelessinvasive and moreapplicable
to the general population thanis NAL. Effortswill also be
focused onmodifyingtechniquesdevelopedinthebiomedi-
cal community to characterize disease processes as early
indicators of chonic pulmonary effects and as suscep-
tibility markers to distinguish between responders and
nonresponders. Techniques to measure these parameters
will help EPA evaluate the efficacy of pollution control
technologies, intervene throughmitigation ofexposures to
individuals showingearlysigns ofdeveloping lung disease
and to better characterize the population at risk from air
pollutants. See Table 3 for a list of near and longer-term
research goals.
Neuroto.xicity. Many EPA regulations are based on
concern over possible neurotoxicity (e.g., from organo-
phosphate pesticides, metals in drinking water, lead in
gasoline). Most measures of neurotoxicity are, however,
invasive and relate only to nonreversible effects following
exposure. One goal of EPA's research on biomarkers of
neurotoxic effects focuses on elucidating relationships
between exposure and outcome for cholinesterase and
Table 3. Future directions in effects biomarker research for selected noncancer end points.
Reproductive/
Pulmonary developmental
toxicity Neurotoxicity toxicity Immunotoxicity
Near term Near term Near term Longer term
Developing methods for Determine the relationship Improve in vitro tests of sperm Develop sensitive
assessing the functional between the cholines- function (male) immunological markers
effects of, and exposure to, terase activity in blood, Improve predictive value of semen (with identifiable
acid aerosols peripheral nervous analysis; also included are responses at threshold
Develop markers for ozone system, and central efforts to improve sampling levels)
degradation products nervous system techniques, standardize results, Develop more quantitative
(DNA, protein products) Determine the relationship and develop suitable sample markers of exposure for
Strengthen interpretation of between the degree of containers (male) dose determination
nasal lavage (NAL) cholinesterase inhibition, Validate measurement of Improve the interpretability
biomarkers neurotoxic esterase testosterone in saliva (male) ofbiomarkers ofimmuno-
inhibition, and neurotoxic Develop methods to assess the toxicity in order to predict
Longer term outcome genetic integrity of sperm (e.g., susceptibility to disease
Develop biomarkers for Determine whether age and/ DNA damage, chromatid Develop and validate
susceptibility (responders or species differences exist structure) and generalized biomarkers that are
versus nonresponders) in the above relationship screening methods for genetic indicators of hyper-
Develop biomarkers as early integrity (male) sensitivity responses
indicators of chronic Longer term Multiple sputum samples for Improve the understanding
effects Gel electrophoretic protein steroids to validate the of the mechanism(s) of
profiles from cerebro- sensitivity ofthe approach chemical-induced immune
spinal fluid (CSF) (female) alterations (i.e., immuno-
Presence of nervous system- Validate measurement of suppression, hypersensi-
specific proteins and leutinizing hormone (ovarian tivity, and autoimmunity)
degradation products in cycle protocol) in mid-cycle and identify biomarkers
CSF, plasma, and urine urine (female)
Presence of immunoglobulins Identify better markers indicative
in serum directed at brain- of early changes in reproductive
derived antigens function (male/female)
Presence of neurotrans-
mitter metabolites in CSF Longer term
Subcellular antigens in blood Develop noninvasive methods for
and urine pointing to the biomarkers ofpreimplantation
extent and localization of development (female)
damage to the nervous Develop better markers of sperm
and other organ systems membrane integrity in vitro
tests ofsperm function (male)
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neurotoxic esterase. Emphasis is placed on determining
relationships between a) cholinesterase activity in blood,
peripheral nervous system, andcentralnervous system; b)
the degree ofcholinesterase and neurotoxic esterase inhi-
bition and neurotoxic outcome; and c) age or species
parameters and these outcomes.
The development of minimally invasive techniques to
detect nervous system-specific proteins is a key goal for
futureresearch. Studies areproceedingalongfourtracks:
a) gel electrophoretic protein profiles from cerebrospinal
fluid (CSF) ofexperimental animals arebeingscreened; b)
CSF from experimental animals is being searched for
neurotransmitter metabolites; c) CSF, plasma, and urine
are being screened for nervous system-specific proteins
and degradation products; d) serum is being screened for
thepresenceofimmunoglobulins directed atbrain-derived
antigens.
The purpose of these efforts is to identify promising
biomarker candidates and to determine which, ifany, can
be detectedinreadilyaccessible tissue. Thisis notashort-
term project. It is anticipated that method development
efforts will continue for the next 5-10 years before valid
molecular markers for nervous system-specific proteins
are developed for use in monitoring human subjects.
Research goals are given in Table 3.
Reproductive/Developmental Toxicity. Humans expe-
rience a significant reproductive failure rate. Exposure to
environmental chemicals has been associated with infer-
tility, and EPA regulates a number of chemicals (e.g.,
dinoseb) based on theirpotential to cause thisproblem. In
developing and using biomarkers to support the Agency's
regulatory activities, EPA researchers will focus initially
on males because ofthe relative ease ofobtaining samples
from men ofreproductive age. Biomarker techniques will
also be used for assessing female infertility, ability to
maintain pregnancy, and heritable genetic mutations.
Initially, the highest priorities for research are to
develop and validate a questionnaire and decision process
for assessment of fertility problems; to develop and vali-
date noninvasive analytical markers fromurine and saliva
(e.g., testosterone) that allow more frequent measures of
endocrine control ofreproductive function; to develop and
validate biomarkers for early pregnancy that distinguish
between pre- and postimplantation loss; and to improve
the predictivevalue ofsemen analysis, including efforts to
develop methods to assess the genetic integrity of sperm
(e.g., DNAdamage, chromatid structure) and generalized
screening methods for genetic integrity. Efforts will also
be initiated to improve sampling techniques, standardize
results, anddevelop suitablesamplecontainers (5). Specific
goals for future research are listed in Table 3.
Immunotoxicity. Manyinvivoandinvitrotests canbe
used to evaluate immune system responses in humans.
Scientists have used these tests to demonstrate allergic
reactions to environmental chemicals and altered immune
function following exposure to environmental pollutants.
However, because of the complexity and interactive
dynamics associated with immune responses, it has been
difficult to interpret these results for risk assessment.
Consequently, with the exception of allergic responses,
risk assessors have had difficulty using immune system
responses as a basis for regulatory decision making.
Research on immunotoxicity biomarkers is a medium
priority for EPA. It will emphasize understanding the
signiflcance of immune response indicators and on using
immune responses to link exposure with effects for the
immune system as well as other target systems. Initial
efforts will focus on developing the rat as a model system
for immunotoxicology studies in order to be able to link
immune parameters to other toxic end points. Normal
immune parameters for cell types, immunoglobulins and
cell growth factors as well as host microbial resistance
parameters are being determined. In the future, animals
willbe challenged and screened to determine the relation-
shipsbetween changes inimmune parameters and signifi-
cant alterations in immune function. The goalis to select a
subsetofimmunemeasuresindicative ofimmune dysfunc-
tion. Emphasis will be placed on compromised resistance
tomicrobes.Alistingoffutureresearch directionsis given
in Table 3.
Hepatotoaxicity. Research on biologic markers for liver
toxicity is a medium priority for EPA. Because of the
variety of serum markers for hepatic damage (14), and
owing to the varying specificity and sensitivity of these
markers, near-term efforts will focus on defining an opti-
mal battery of serum biomarkers suitable for routine
environmental monitoring. Efforts are also planned on
serum enzyme tests and noninvasive tests for hepatic
fibrosis and cirrhosis.
Other Effects. Although validation of biomarkers for
otherendpoints (e.g.,renaltoxicity, dermaleffects)isnota
priority for EPA at this time, the Agency will continue to
monitor progress by others, such as the National Insti-
tutes of Health, in developing, validating, and applying
relevant methodologies.
Summary
Public and private actions to protect citizens' health
from the adverse effects of environmental pollutants are
predicated on an established or postulated link between
human exposures and resulting disease or injury. The
actualhealthrisksexperiencedbyanindividual aredepen-
dent onthe seriousness ofthe exposure, thetoxicityofthe
pollutant or mixture ofpollutants, and his or her suscep-
tibility to the environmental insult based on factors such
as health status, diet, age, or genetic predisposition.
Biologic markers are measurements of environmental
pollutants or their biological consequences after the con-
taminants have crossed one ofthe body's boundaries and
entered tissues or fluids. Depending on the nature of a
particular biomarker and our understanding of the cas-
cade of events from exposure to effects, measurements
mayprovide either qualitative or quantitative information
about exposures (i.e., exposure markers), health effects
(i.e., effect markers), or susceptibility (i.e., susceptibility
markers).
Biologicmarkerspromisetorevolutionizethecharacter-
ization ofenvironmental health risks. By reducing critical
uncertainties their application will build a stronger scien-
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tific basis on which to make decisions about safeguarding
public health. This, in turn, will lead to better policy and
regulatory decisions and more efficacious use of scarce
resources to safeguard public health.
Because the Agency is involved in all phases of the
biologic marker issue, EPA scientists have identified im-
portant research questions, prioritized associated re-
search needs, and developed a strategy to address those
needs. The preceding discussion has summarized the
rationale for the EPA biomarkers research program and
outlined future research directions. Ultimately, the suc-
cess of the program will be measured by the degree to
whichresultsimprove ourabilityto assessthe seriousness
ofenvironmental health risks.
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